Latest news
Entrada Reports Early Functional Benefit in Phase 1/2 Duchenne Study of ENTR-601-44 - BioPharm InternationalBioPharm International · Fri, 07 Aug 2026 19:52:06 GMTEntrada Therapeutics (Nasdaq: TRDA) reports Q2 2026 results and sets DMD, DM1 data timeline - Stock TitanStock Titan · Wed, 05 Aug 2026 11:04:58 GMTEntrada Therapeutics (TRDA) holder sells shares, still reports 1.09M stake - Stock TitanStock Titan · Mon, 03 Aug 2026 21:33:18 GMT